Decentralized study

From the Desk of Dr. Danielle Meadows,
Vice President of Research Programs & Operations

This month, I want to spend some time on a concept that has a huge impact on how studies are designed (the first stage of the research process): decentralization.

Decentralized studies are a more modern way of conducting clinical research, and they offer some major benefits for participants and researchers, especially for multi-system chronic complex diseases like ME/CFS, Long COVID, and related diseases.

The Heart of the Matter

• Traditional clinical studies require participants to travel to a single site, which is a barrier that leaves many people unable to take part in research.
• Decentralized studies offer more flexible options for participating in research like local lab visits, home collection kits, or virtual check-ins, so participants can contribute in the way that works best for their health and their lives.
• For people living with ME/CFS, where even a short trip can trigger extended periods of worsening symptoms, this flexibility makes meaningful participation in research possible for people who are housebound.
• OMF's Clinical Trials Network Lite (CTN Lite) initiative will include treatment trials that use decentralized study designs, making the studies more accessible to people with more severe ME/CFS. Read more about CTN Lite on our website.

What is a decentralized study?

A decentralized clinical research study is designed around the participant—not around a single research location. Rather than requiring everyone to travel to one central clinic or site, decentralized studies offer flexible options like the following: participants may visit a convenient local lab, have a collection kit sent to their home, virtually connect with a researcher, or enroll through one of many participating sites closer to where they live. The goal is to remove barriers and give participants meaningful choices in how they take part.

The benefits of decentralized studies

Traditional clinical studies are built around the assumption that participants can travel to—and repeatedly visit—a single research center. For many people, that assumption simply does not hold. Decentralized studies change that by:

• Expanding who can participate – By offering multiple ways to enroll and contribute, decentralized studies open the door to a far broader and more diverse group of participants—including those who live far from major research centers or are unable to leave their home.
• Producing richer, more representative data – When study populations reflect the real-world range of patients—across geography, disease severity, and circumstance—the findings are stronger and more widely applicable.
• Reducing dropout – Flexible participation options lower the burden of staying in a study, which means more people complete it and the data becomes more reliable.

Why this matters for ME/CFS

For people living with ME/CFS, post-exertional malaise (PEM) means that physical or cognitive effort—including travel to a clinic—can trigger a serious worsening of symptoms lasting days, weeks, or longer. Traditional study designs have long excluded the patients who need research the most: those who are housebound, severely ill, or simply too far from a research site to participate.

Decentralized research tries to honor the reality of life with ME/CFS, by allowing participants to choose the path that works for their health and their lives. This leads to more representative data and, ultimately, more meaningful answers. OMF's streamlined approach to a Clinical Trials Network (CTN Lite) will utilize decentralized study designs for precision medicine treatment trials. Learn more about the initiative on our website.